Clinical Trial: Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07510724) titled 'Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab' on Feb. 03.

Brief Summary: The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.

Study Start Date: Dec. 23, 2025

Study Type: OBSERVATIONAL

Condition: Small Cell Lung Cancer (SCLC) Non-...